However, extensive evidence suggests that the aberrant activation of the Keap1-NRF2 pathway in tumor cells leads to persistently elevated NRF2 levels, contributing to chemoradiotherapy resistance across various cancers [14, 15]. The gene discussed is NFE2L2; the disease is cancer.